Clinical Trial Update: Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing lower-concentration Dysport targeted to the neuromuscular junction versus current clinical practice in arm spasticity was terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spasticity

Drugs mentioned

• Dysport (abobotulinumtoxinA)

Snippet

Sponsor: Ipsen | Conditions: Arm Spasticity | Phase 3 | Status: TERMINATED | Results posted: 2019-02-18